Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients
Video navigation menu
The EMPA-REG CV OUTCOME trial of empagliflozin 0:00
Heart failure outcomes in the EMPA-REG OUTCOME trial 1:46
Does presence of HF at baseline drive the HF outcomes? 2:15
What do these results mean for use of diabetes medication in high-risk individuals? 2:58
Share this page with your colleagues and friends: